In brief
The expiration of the semaglutide patent in India marks a pivotal moment in the fight against obesity as domestic companies prepare to launch cheaper generics of weight-loss drugs like Wegovy and Ozempic. Analysts predict a market surge that could make these effective treatments accessible to a broader population, while also highlighting potential risks related to quality control and misuse. Experts underscore the need for careful regulation as the market expands.
India could soon get a lot thinner - at least in theory.
On Friday the patent on semaglutide - the molecule behind Danish drugmaker Novo Nordisk's blockbuster weight-loss drugs Wegovy and Ozempic - expires in the country. This will allow domestic pharmaceutical companies to release cheaper copies or generics, triggering a rush of competition that could slash prices by more than half and rapidly expand access for people in India, and eventually in other countries too.
Investment bank Jefferies has called it a potential magic-pill moment for India, predicting the semaglutide market could eventually reach $1bn domestically with the right pricing and uptake. Analysts expect around 50 branded semaglutide generics to enter the market within months, a familiar pattern in India's fiercely competitive pharmaceutical industry. With the diabetes drug sitagliptin recently going off patent, about 30 branded versions appeared within a month and nearly 100 within a year.
India's pharmaceutical industry, currently worth about $60bn, is expected to double by 2030, built on generics that set the stage for fierce competition over semaglutide. Once confined to affluent patients due to high costs, effective weight-loss drugs may soon become common.
GLP-1 drugs like semaglutide, originally developed for diabetes, are being hailed as game changers for weight loss, offering unprecedented results. These medications mimic a hormone regulating appetite and blood sugar, leading to effective and sustained weight loss. Current treatments are expensive, but generics could push monthly costs down to as low as $36-54, presenting a significant opportunity for broader access.
Despite the potential benefits, experts urge caution regarding quality control and responsible usage. There are fears over potential misuse by individuals without medical supervision, possibly promoted through social media. Physicians stress the importance of making these drugs available under medical guidance, given the serious nature of obesity and associated health risks.
In summary, while India stands on the brink of a low-cost weight-loss drug revolution, the journey will require careful regulation and public education to ensure that the benefits can be realized safely and effectively.
